| # | Title | Journal | Year | Citations |
|---|
| 1 | Coagulation abnormalities and thrombosis in patients with COVID-19 | Lancet Haematology,the | 2020 | 1,186 |
| 2 | Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study | Lancet Haematology,the | 2020 | 848 |
| 3 | Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial | Lancet Haematology,the | 2016 | 442 |
| 4 | Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study | Lancet Haematology,the | 2020 | 430 |
| 5 | Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study | Lancet Haematology,the | 2020 | 383 |
| 6 | Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study | Lancet Haematology,the | 2016 | 359 |
| 7 | Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study | Lancet Haematology,the | 2016 | 344 |
| 8 | Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study | Lancet Haematology,the | 2017 | 338 |
| 9 | One million haemopoietic stem-cell transplants: a retrospective observational study | Lancet Haematology,the | 2015 | 329 |
| 10 | Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study | Lancet Haematology,the | 2015 | 325 |
| 11 | Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19 | Lancet Haematology,the | 2020 | 323 |
| 12 | Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial | Lancet Haematology,the | 2016 | 322 |
| 13 | Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation | Lancet Haematology,the | 2020 | 319 |
| 14 | Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial | Lancet Haematology,the | 2016 | 311 |
| 15 | Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study | Lancet Haematology,the | 2016 | 307 |
| 16 | Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials | Lancet Haematology,the | 2017 | 276 |
| 17 | Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study | Lancet Haematology,the | 2021 | 271 |
| 18 | Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial | Lancet Haematology,the | 2015 | 261 |
| 19 | Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial | Lancet Haematology,the | 2017 | 258 |
| 20 | Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study | Lancet Haematology,the | 2019 | 252 |
| 21 | Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials | Lancet Haematology,the | 2014 | 244 |
| 22 | Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study | Lancet Haematology,the | 2020 | 244 |
| 23 | Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study | Lancet Haematology,the | 2017 | 243 |
| 24 | Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial | Lancet Haematology,the | 2017 | 236 |
| 25 | A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study | Lancet Haematology,the | 2015 | 232 |
| 26 | Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis | Lancet Haematology,the | 2015 | 228 |
| 27 | Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials | Lancet Haematology,the | 2015 | 227 |
| 28 | Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial | Lancet Haematology,the | 2017 | 224 |
| 29 | A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts | Lancet Haematology,the | 2018 | 219 |
| 30 | Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy | Lancet Haematology,the | 2016 | 218 |
| 31 | Effects of the COVID-19 pandemic on supply and use of blood for transfusion | Lancet Haematology,the | 2020 | 216 |
| 32 | Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study | Lancet Haematology,the | 2016 | 215 |
| 33 | Idiopathic multicentric Castleman's disease: a systematic literature review | Lancet Haematology,the | 2016 | 213 |
| 34 | Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial | Lancet Haematology,the | 2018 | 211 |
| 35 | A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial | Lancet Haematology,the | 2019 | 211 |
| 36 | Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study | Lancet Haematology,the | 2021 | 211 |
| 37 | 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial | Lancet Haematology,the | 2020 | 201 |
| 38 | Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial | Lancet Haematology,the | 2020 | 201 |
| 39 | Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203) | Lancet Haematology,the | 2019 | 200 |
| 40 | Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study | Lancet Haematology,the | 2020 | 199 |
| 41 | Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis | Lancet Haematology,the | 2016 | 197 |
| 42 | Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study | Lancet Haematology,the | 2019 | 195 |
| 43 | Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial | Lancet Haematology,the | 2019 | 194 |
| 44 | Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study | Lancet Haematology,the | 2018 | 190 |
| 45 | Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS) | Lancet Haematology,the | 2019 | 184 |
| 46 | Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial | Lancet Haematology,the | 2017 | 181 |
| 47 | Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial | Lancet Haematology,the | 2019 | 176 |
| 48 | Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial | Lancet Haematology,the | 2019 | 174 |
| 49 | COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year | Lancet Haematology,the | 2021 | 174 |
| 50 | Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial | Lancet Haematology,the | 2020 | 173 |
